期刊
IMMUNOTHERAPY
卷 10, 期 9, 页码 797-805出版社
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2017-0187
关键词
checkpoint inhibitors; FDG-PET; immune-related response criteria; immune-PET; irRECIST; NSCLC
类别
资金
- Italian Association for Research on Cancer (Associazione Italiana per la Ricerca sul Cancro [AIRC])
- AIRC [18923]
The treatment algorithm of advanced non-small-cell lung cancer is rapidly evolving. This result is mostly related to the availability in clinical practice of checkpoint inhibitors targeting the programmed death-1 (PD-1) and its ligands (PD-Ls) immunosuppressive pathway. Although patient's selection in the first-line setting relies essentially on high levels of PD-L1 tumor expression, treatment choice in pretreated patients is more challenging and, although clinical and biological characteristics might be of help, there is an urgent need for novel tools to better identify sensitive and resistant patients. In this context, the integration of molecular markers and immune-PET imaging might represent a potentially effective strategy to refine patient selection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据